Article

Suresh Ramalingam on Toxicities Associated With Immunotherapy in Different Disease Types

Author(s):

Suresh S. Ramalingam

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
CURE spoke with Andy Guinigundo to discuss the role that biomarkers play for patients with breast cancer.
Colorectal cancer is on the rise among younger adults, although potential explanations for the cause of this trend are likely years away.
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
Image of doctor.
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
Related Content
Image of legs.
April 6th 2025

Raising Awareness for Lymphedema Following a Cancer Diagnosis

Ryan Scott
Dr. Sheri Yolanda Prentiss explores the challenges patients face in accessing lymphedema compression garments following cancer treatment.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population: © Konstantin Yuganov - stock.adobe.com
March 28th 2025

Childhood Cancer Survivors May Experience Sooner Aging-Related Disease

Alex Biese
Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.
Itolizumab did not improve response rates at Day 29 in acute GVHD; however, the therapy showed significant benefits in long-term outcomes: © stock.adobe.com
March 27th 2025

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

Ryan Scott
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.